《大行報告》瑞信上調財險(02328.HK)目標價至8.6元 評級「中性」
瑞信發表報告,將中國財險(02328.HK)2022至2023財年每股盈利預測上調約1%,目標價相應由8.3元上調至8.6元,維持「中性」評級,反映估值合理。
瑞信指,財險上半年原保險保費收入按年升9.9%,意味次季升幅為7.1%,增長放緩主要是由於疫情影響新車銷售,令相關保費收入按季減少,而農業保費收入亦放緩。該行料2022財年總保費按年增長9.5%,即下半年增幅為9%。
瑞信預計財險上半年除稅後純利(NPAT)增長15%至190億元人民幣,意味著第二季反彈超過30%,受惠於承保利潤增長和A股好轉;料2022財年除稅後純利增長為19%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.